Cognition Therapeutics, Inc. (NASDAQ:CGTX) Sees Significant Increase in Short Interest

Cognition Therapeutics, Inc. (NASDAQ:CGTXGet Rating) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 8,700 shares, a growth of 52.6% from the March 15th total of 5,700 shares. Based on an average trading volume of 82,200 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company’s shares are sold short.

Several analysts have recently issued reports on CGTX shares. B. Riley lowered their price objective on shares of Cognition Therapeutics from $27.00 to $20.00 in a research note on Monday, January 24th. Zacks Investment Research lowered Cognition Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, April 4th.

Cognition Therapeutics stock opened at $2.90 on Friday. The stock has a fifty day simple moving average of $3.06. Cognition Therapeutics has a 12 month low of $2.31 and a 12 month high of $13.80.

A number of hedge funds have recently bought and sold shares of CGTX. BlackRock Inc. bought a new stake in Cognition Therapeutics in the fourth quarter valued at $51,000. Bangor Savings Bank bought a new stake in Cognition Therapeutics in the first quarter valued at $51,000. Renaissance Technologies LLC bought a new stake in Cognition Therapeutics in the fourth quarter valued at $74,000. AIGH Capital Management LLC bought a new stake in Cognition Therapeutics in the fourth quarter valued at $161,000. Finally, B. Riley Financial Inc. bought a new stake in Cognition Therapeutics in the fourth quarter valued at $195,000. Institutional investors own 18.26% of the company’s stock.

About Cognition Therapeutics (Get Rating)

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD).

Featured Stories

Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.